NX-5948 Bioavailability Study in Healthy Subjects

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Nurix Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it requires participants to be medically healthy with no significant medical history. This suggests that participants should not be on any regular medications for ongoing health issues.

Eligibility Criteria

This trial is for healthy individuals. It's designed to understand how the body absorbs a new medication, NX-5948, in tablet versus capsule form and how food or an acid-reducing drug like Esomeprazole affects this process.

Inclusion Criteria

I am a healthy adult between 19 and 55 years old.

Exclusion Criteria

I have a history of specific heart rhythm problems or have a pacemaker.

I have had or currently have a skin infection.

I am mentally capable and emotionally stable to participate in a study.

I am pregnant.

I or my family have a history of abnormal heart rhythms or sudden cardiac death.

I have or had adrenal insufficiency.

I have been treated with NX-5948 before.

I have had stomach or gallbladder surgery that may affect how a drug works in my body.

Participant Groups

The study tests the absorption (bioavailability) of NX-5948 when taken as a tablet compared to a capsule. Participants will also see how taking it with food or alongside Esomeprazole alters its absorption into the body.

2Treatment groups

Experimental Treatment

Group I: NX-5948 tablet combined with esomeprazole under fasted conditionsExperimental Treatment3 Interventions

Cohort 2: Single dose of NX-5948 tablet combined with esomeprazole under fasted conditions. Also, a single dose of NX-5948 capsule under fasted conditions.

Group II: NX-5948 tablet and capsule under fasted and fed conditionsExperimental Treatment2 Interventions

Cohort 1: Single dose of NX-5948 tablet under fasted and fed conditions. Also, single dose of NX-5948 capsule under fasted conditions.